株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

網膜症:パイプライン分析

Retinopathy - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 246027
出版日 ページ情報 英文 79 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.77円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
網膜症:パイプライン分析 Retinopathy - Pipeline Review, H1 2016
出版日: 2016年06月08日 ページ情報: 英文 79 Pages
概要

網膜症は、網膜−−目の後ろ半分を占める、光に敏感な細胞のかたまり−−がかかる疾患のことを指します。網膜には、目で見たものを電気信号に変換する神経細胞が集中しています。この信号は脳に転送されて、視覚情報として解釈されます。

当レポートでは、世界各国での網膜症治療用のパイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要(製品概要、機能メカニズム、研究開発(R&D)の進展状況)、最新の業界動向などを調査して、その結果をお届けします。

イントロダクション

  • 分析範囲

網膜症の概要

治療薬の開発

  • 網膜症向けパイプライン製品:概要
  • 網膜症向けパイプライン製品:比較分析

各企業で開発中の網膜症治療薬

大学/研究機関で研究中の網膜症治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

網膜症治療薬:開発中の製品の一覧(企業別)

網膜症治療薬:研究中の製品の一覧(大学/研究機関別)

網膜症治療薬の開発に従事している企業

  • Acucela Inc.
  • Biomar Microbial Technologies
  • Biophytis SAS
  • Edison Pharmaceuticals, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Insmed Incorporated
  • Navigen Pharmaceuticals, Inc.
  • RedHill Biopharma Ltd

網膜症:治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 機能メカニズム別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

網膜症治療薬:最新のパイプライン製品

網膜症治療薬:開発が休止状態の製品

網膜症治療薬:開発が中止された製品

網膜症関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8185IDB

Summary

Global Markets Direct's, 'Retinopathy - Pipeline Review, H1 2016', provides an overview of the Retinopathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Retinopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Retinopathy and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Retinopathy
  • The report reviews pipeline therapeutics for Retinopathy by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Retinopathy therapeutics and enlists all their major and minor projects
  • The report assesses Retinopathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Retinopathy

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Retinopathy
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Retinopathy pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Retinopathy Overview
  • Therapeutics Development
    • Pipeline Products for Retinopathy - Overview
    • Pipeline Products for Retinopathy - Comparative Analysis
  • Retinopathy - Therapeutics under Development by Companies
  • Retinopathy - Therapeutics under Investigation by Universities/Institutes
  • Retinopathy - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Retinopathy - Products under Development by Companies
  • Retinopathy - Products under Investigation by Universities/Institutes
  • Retinopathy - Companies Involved in Therapeutics Development
    • Acucela Inc.
    • Biomar Microbial Technologies
    • Biophytis SAS
    • Edison Pharmaceuticals, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Insmed Incorporated
    • Navigen Pharmaceuticals, Inc.
    • RedHill Biopharma Ltd.
  • Retinopathy - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ABC-294640 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AP-202 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BIO-201 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BIO-203 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • emixustat hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IB-09A0133 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IB-12A157 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • mecasermin rinfabate (recombinant) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NAV-2729 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • R-200 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ranibizumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein for Cancer and Diabetic Retinopathy - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein for Oncology and Ophthalmology - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Retinopathy of Prematurity - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Eya Tyrosine Phosphatase for Solid Tumors and Retinopathy - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • vatiquinone - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Retinopathy - Recent Pipeline Updates
  • Retinopathy - Dormant Projects
  • Retinopathy - Discontinued Products
  • Retinopathy - Product Development Milestones
    • Featured News & Press Releases
      • Jan 21, 2009: Insmed And Premacure Announce European Orphan Designation For IPLEX In Retinopathy Of Prematurity In Infants
      • Apr 29, 2008: Acucela Presents Preclinical Data From Retinopathy Study Demonstrating Improvement In Retinal Abnormalities
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Retinopathy, H1 2016
  • Number of Products under Development for Retinopathy - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Retinopathy - Pipeline by Acucela Inc., H1 2016
  • Retinopathy - Pipeline by Biomar Microbial Technologies, H1 2016
  • Retinopathy - Pipeline by Biophytis SAS, H1 2016
  • Retinopathy - Pipeline by Edison Pharmaceuticals, Inc., H1 2016
  • Retinopathy - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
  • Retinopathy - Pipeline by Insmed Incorporated, H1 2016
  • Retinopathy - Pipeline by Navigen Pharmaceuticals, Inc., H1 2016
  • Retinopathy - Pipeline by RedHill Biopharma Ltd., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Retinopathy Therapeutics - Recent Pipeline Updates, H1 2016
  • Retinopathy - Dormant Projects, H1 2016
  • Retinopathy - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Retinopathy, H1 2016
  • Number of Products under Development for Retinopathy - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Top 10 Routes of Administration, H1 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top